Celltrion unveils global clinical trial PhaseI result of CT-P10

November 1, 2013 11:34 AM

Celltrion Inc. revealed the results of the phase 1 of global clinical trial of CT-P10 conducted with 150 patients who did not previously show response to TNF-alpha inhibitors for their rheumatoid arthritis at the ACR(American College of Rheumatology) 2013.

CT-P10, third biosimilar candidate developed by Celltrion, is a kin version of rituximab, biologic agent for rheumatoid arthritis and certain other kinds of hematologic diseases. The study revealed that CT-P10 was equivalent to the original drug in all aspects observed in pharmacokinetics, efficacy and safety.

The global clinical trial Phase I was conducted at thirty-eight hospitals in eight countries with 150 patients who did not respond to TNF-alpha inhibitors over 24 weeks.  To demonstrate pharmacokinetic equivalence, parameters such as AUC(Area Under the Curve), Cmax(Peak serum Concentration) were evaluated, and for evaluating clinical comparability, ACR20/50/70, ESR, CPR were evaluated. After 24 week from the first administration, at the evaluation time point, in all clinical domains, no significant statistical differences were observed between CT-P10 and its originator. Immunogenicity were observed in both arms and developing immunogenicity affected to overall responses and PKs. The proportion of patients who developed Antidrug Antibodies (ADA) during the study was similar in both treatment groups for up to week 24.  The safety profile for CT-P10 and rituximab were comparable in all categories (TEAEs, SAEs, infection and infusion-related reactions) at 24 week

An official from Celltrion said “Development of our third product is going very smoothly with successful clinical trial phase 1 result of CT-P10″. Celltrion is preparing for global clinical trial phase 3. The official further elaborated “Announcement of successful clinical trial phase 1 result of CT-P10 is meaningful for Celltrion as this announcement consolidates company’s position as a leader in biosimilar development.”

The original product of CT-P10 is used to treat not only rheumatoid arthritis but also for non-Hodgkin’s lymphoma. The original product of CT-P10 is a blockbuster mAb which recorded sales of USD 7.1 billion world-wide last year.

ACR is one of the largest global rheumatology conferences along with EULAR, with more than 15,000 medical doctors, health professionals, and clinical trial experts participate in ACR annually.


Source: Celltrion press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!